Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Halozyme Therapeutic (HALO)

Halozyme Therapeutic (HALO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Halozyme Therapeutic 11388 SORRENTO VALLEY ROAD SAN DIEGO CA 92121 USA

P: 858-794-8889 F: 858-704-8311

Description:

Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.

Key Statistics

Overview:

Market Capitalization, $K 6,856,651
Enterprise Value, $K 6,992,411
Shares Outstanding, K 135,213
Annual Sales, $ 443,310 K
Annual Net Income, $ 402,710 K
Last Quarter Sales, $ 208,980 K
Last Quarter Net Income, $ 61,630 K
60-Month Beta 1.23
% of Insider Shareholders 2.30%
% of Institutional Shareholders 96.32%
Float, K 132,103
% Float 97.70%
Short Volume Ratio 0.48

Growth:

1-Year Return 56.82%
3-Year Return 167.18%
5-Year Return 176.05%
5-Year Revenue Growth 202.21%
5-Year Earnings Growth 329.63%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.74 on 11/08/22
Next Earnings Date 02/28/23
Earnings Per Share ttm 2.02
EPS Growth vs. Prev Qtr 40.00%
EPS Growth vs. Prev Year 34.62%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

HALO Ratios

Ratio
Price/Earnings ttm 26.38
Price/Earnings forward 20.06
Price/Earnings to Growth 0.69
Return-on-Equity % 134.71%
Return-on-Assets % 19.31%
Profit Margin % 90.84
Net Margin % -95.02
Debt/Equity 15.37
Price/Sales 12.39
Price/Cash Flow 26.57
Price/Book 75.69
Book Value/Share 0.70
Interest Coverage 34.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar